These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9772065)

  • 21. Recurrent ischemic colitis in a patient with leiden factor V mutation and systemic lupus erythematous with antiphospholipid syndrome.
    Heyn J; Buhmann S; Ladurner R; Schiemann U; Ozimek A; Kirchhoff C; Hallfeldt KK; Mussack T
    Eur J Med Res; 2008 Apr; 13(4):182-4. PubMed ID: 18504175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
    Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
    Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
    Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
    Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
    Giordano P; Sabato V; Schettini F; De Mattia D; Iolascon A
    Haematologica; 1997; 82(6):698-700. PubMed ID: 9499670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R; Quehenberger P; Wu JR; Wilmer M
    Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene.
    Santamaría A; Mateo J; Oliver A; Menéndez B; Souto JC; Borrell M; Soria JM; Tirado I; Fontcuberta J
    Haematologica; 2001 Sep; 86(9):965-71. PubMed ID: 11532625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
    Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
    Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombophilias and recurrent pregnancy loss.
    Kutteh WH; Triplett DA
    Semin Reprod Med; 2006 Feb; 24(1):54-66. PubMed ID: 16418978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated protein C resistance in anterior ischaemic optic neuropathy.
    Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
    Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral contraceptive-induced central retinal artery occlusion.
    Rekhi GS; Dheer S
    J Assoc Physicians India; 2002 Aug; 50():1084-5. PubMed ID: 12421041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden.
    van Vliet HA; Rodrigues SP; Snieders MN; van der Meer FJ; Frolich M; Rosendaal FR; Rosing J; Helmerhorst FM
    Thromb Res; 2008; 121(6):757-61. PubMed ID: 17936879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
    Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Factor V Leiden mutation. Successful outcome of a pregnancy after heparin therapy].
    Mazzarella CR; Del Bianco A; Pietropaolo F
    Minerva Ginecol; 2003 Feb; 55(1):81-5. PubMed ID: 12598848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
    Yossepowitch O; Chajek-Shaul T; Rubinow A; Haviv YS; Safadi R
    Eur J Med Res; 1997 Aug; 2(8):355-7. PubMed ID: 9262489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of coagulation disorders in mesenteric ischemia].
    Maloisel F
    J Chir (Paris); 1996; 133(9-10):442-7. PubMed ID: 9296019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
    Dahlbäck B
    J Lab Clin Med; 1995 May; 125(5):566-71. PubMed ID: 7738422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.